A recently developed medication encourages people with cocaine use disorder to reduce their intake of the stimulant – a step ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

In clinical trial results released today, an experimental drug initially developed by Novartis was found to reduce cocaine use in people with cocaine use disorder. Scientists at Novartis led the ...

By the time Monte Wooden had his first heart attack, nothing about his lifestyle explained it. He didn’t smoke. His blood ...

This development comes at a time when pharmaceutical firms are discontinuing discovery efforts in next-generation COVID-19 ...

Even statins don’t work on risk factor called lipoprotein (a) that quickly clings to arteries and narrows them ...

We, like so many others, have been forced to take steps to extend our cash runway,” said Tango’s CEO, citing the “extremely challenging financial markets.” ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

A potential breakthrough in cardiovascular medicine has emerged with the development of lepodisiran, an experimental drug by pharmaceutical company Eli Lilly. The drug has demonstrated an ...

“Nearly a quarter of the world’s population has elevated levels of Lp (a), putting them at a significantly higher risk of cardiovascular events such as heart attacks and strokes,” said Steven Nissen, ...